Delamanid News
Delamanid currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Delamanid with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of...
- Evidence level: L5
- Predicted indications (20):
- multidrug-resistant tuberculosis (99.9%)
- tuberculosis, bovine (99.9%)
- tuberculoma (99.9%)
- tuberculosis, avian (99.9%)
- inactive tuberculosis (99.9%)
- tuberculous ascites (99.9%)
- allergic urticaria (99.6%)
- cutaneous tuberculosis (99.1%)
- fascioliasis (99.0%)
- inhalational botulism (98.9%)
- urea cycle disorder (98.8%)
- toxin-mediated infectious botulism (98.7%)
- hyperamylasemia (98.6%)
- polyclonal hyperviscosity syndrome (98.6%)
- leishmaniasis, diffuse cutaneous (98.6%)
- congenital analbuminemia (98.4%)
- Clostridium infectious disease (98.2%)
- extrapulmonary tuberculosis (98.1%)
- blood group incompatibility (98.0%)
- vulvovaginal candidiasis (97.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.